SUBSCRIBE
SUBSCRIBE

Depression

Pictured: Anxious man with his head in his hands/i
Drug Development
Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study
An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced symptom severity in adults with major depressive disorder.
April 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: An artist’s illustration of mental health concept
Drug Development
Intra-Cellular Touts Phase III Major Depressive Disorder Results for Antipsychotic Drug
Already approved in schizophrenia and bipolar depression, Intra-Cellular Therapies reported strong late-stage data Tuesday for its antipsychotic Caplyta in major depressive disorder.
April 16, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Anxious man with his head in his hands/i
Drug Development
Engrail Raises $157M in Oversubscribed Series B to Move Neuro Pipeline Forward
Engrail Therapeutics’ latest financing round will give it enough funds to advance its candidates for neuropsychiatric and neurodevelopmental disorders through clinical development.
March 19, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: A suited arm pointing a dart at a bullse
Deals
Psychedelics, Solid Tumors Will Be Key Focuses for Investors in 2024
After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.
March 5, 2024
 · 
5 min read
 · 
Heather McKenzie
Load More
PRESS RELEASES
Press Releases
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
April 9, 2026
 · 
9 min read
Press Releases
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
April 8, 2026
 · 
7 min read
Press Releases
Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants
March 30, 2026
 · 
3 min read
Press Releases
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network
March 30, 2026
 · 
8 min read
Press Releases
New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting
March 30, 2026
 · 
10 min read
Press Releases
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
March 25, 2026
 · 
6 min read
Press Releases
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
March 17, 2026
 · 
5 min read
Press Releases
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
March 16, 2026
 · 
11 min read
Press Releases
Radial Announces Publication of Landmark Study of Accelerated Deep TMS for Depression
March 13, 2026
 · 
2 min read
Press Releases
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
March 10, 2026
 · 
3 min read
Press Releases
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
March 10, 2026
 · 
7 min read
Press Releases
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
March 9, 2026
 · 
12 min read
Press Releases
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
March 9, 2026
 · 
11 min read
Press Releases
Soterix Medical Announces Clearance of SPRY Transcranial Magnetic Stimulation (TMS) Therapy for the treatment of Major Depression
March 5, 2026
 · 
2 min read
Press Releases
Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
March 4, 2026
 · 
8 min read
Press Releases
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
March 3, 2026
 · 
7 min read
Press Releases
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
March 2, 2026
 · 
9 min read
Press Releases
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
February 24, 2026
 · 
6 min read
Press Releases
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
February 20, 2026
 · 
3 min read
Press Releases
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
February 17, 2026
 · 
9 min read
Load More